AR and breast carcinoma: To assess the potential clinical relevance of PART1/AR signaling in breast cancer, we assessed the correlation of PART1 expression with the androgen signaling gene panel (containing 10 genes, from cBioPortal) across breast cancer subtypes in two breast cancer patient tumor datasets (Figure S1).